/
/
ASH 2021: Myeloma Antibody Symposium Kicks Off ASH for HealthTree Foundation
ASH 2021: Myeloma Antibody Symposium Kicks Off ASH for HealthTree Foundation image
ASH 2021: Myeloma Antibody Symposium Kicks Off ASH for HealthTree Foundation
Posted Nov 19, 2021

Antibody-based cancer treatment updates will be among the stars of the show for myeloma physicians and researchers attending the American Society of Hematology (ASH) annual meeting in Atlanta, GA from December 11-14, 2021.  In response to the unique conditions posed by the pandemic, this will be the first time one of these programs will be available to patients around the world.  The free virtual program does not require registration for the ASH meeting. 

A Is for Antibodies in Myeloma: Insights and Patient Voices Along the Therapeutic Journey

The symposium will feature three leading myeloma experts who will be among many professional presentations held the day before the official ASH opening that has become known as “Super Friday.”  Scheduled for Friday, December 10 from 7:00-9:00 am Eastern Standard Time, the program will feature:

  • Suzanne Lentzsch, MD, PhD, (chair), Professor of Clinical Medicine and Director of the Multiple Myeloma and Amyloidosis Program at the Columbia University Herbert Irving Comprehensive Cancer Center
  • Noa Biran, MD, Assistant Professor, Hackensack University Medical Center, John Theurer Cancer Center
  • Ajay Nooka, MD, MPH, FACP, Associate Professor, Emory University, Winship Cancer Institute

Recent and expected FDA drug approvals of antibody-based approaches have been shown to provide durable efficacy in many different clinical settings.  As the therapeutic benefits of specific targets are better understood, the time for combining them for greater efficacy is fast approaching.

Any patient can register for free to view the online webcast. 

 

Register for webcast

 

This event will help viewers to better understand the alphabet soup of targets—BCMA, CD38, SLAMF7, GPRC5D, FCRH5—that are key to their treatment today and even more important in the future.

The HealthTree Foundation is partnering with PeerView, a company specializing in professional continuing medical education programs for a variety of cancers, and Medical Learning, Inc. to host the symposium.

Myeloma Coaches will be featured in brief videos following each speaker’s presentation to provide their perspectives on how treatment with novel antibodies impacted their lives.

Join us live on Friday, December 10 if you can.  Registration is open!

A recording of the event will be made available in early 2022.

 

register for webcast

 

 

The author Greg Brozeit

about the author
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

More MC Events Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811